<DOC>
	<DOCNO>NCT00168909</DOCNO>
	<brief_summary>The purpose study evaluate effect alfacalcidol 1 µg daily number faller postmenopausal , alendronate-treated , osteopenic osteoporotic woman . primary outcome = number faller ( patient least one locomotor fall incl.mixed fall )</brief_summary>
	<brief_title>Influence Alfacalcidol Falls Osteopenic/Osteoporotic Postmenopausal Women ( ALFA Study )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>age &gt; 65 year postmenopausal woman osteopenia/osteoporosis define WHO criteria Neoplasm severe disease life expectancy le one year expectation rapid worsen within one year Chronic inflammatory rheumatoid disease Arthritis continuous pain influence locomotion Inflammatory metabolic bone disease , exclude osteoporosis . Subjects antiosteoporotic medication willing switch alendronate treatment . Estrogen treatment continue 25OHVitamin D3 &lt; 12 ng/ml ( 12 ng/ml = 30 mmol/L ) Systemic corticosteroid treatment one month within previous 12 month Intolerability alfacalcidol Hypercalcaemia ( &gt; 2,7 mmol/l ) Milk alkali syndrome Uncorrected , severe visual impairment Creatinin &gt; 2.5 mg/dl ( &gt; 220 µmol/L )</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>frailty</keyword>
	<keyword>fall</keyword>
</DOC>